Mielnik, Catharine ASugamori, Kim SFinlay, David BThorpe, Hayley H ASchapira, MatthieuSivananthan, NirunthanLi, Chun Kitlam, Vincent MHarrington, SeanAbdelrahman, Mostafa HTrembleau, Laurent ABurnham, W. McIntyreKhokhar, Jibran YSalahpour, AliRamsey, Amy JGlass, MichelleGreig, Iain R.Ross, Ruth A.2020-11-032020-11-032021-01-31Mielnik, C A, Sugamori, K S, Finlay, D B, Thorpe, H H A, Schapira, M, Sivananthan, N, Li, C K, lam, V M, Harrington, S, Abdelrahman, M H, Trembleau, L A, Burnham, W M, Khokhar, J Y, Salahpour, A, Ramsey, A J, Glass, M, Greig, I R & Ross, R A 2021, 'A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models', Neuropsychopharmacology, vol. 46, no. 2, pp. 413-422. https://doi.org/10.1038/s41386-020-00876-50893-133XORCID: /0000-0003-0603-3383/work/82958684ORCID: /0000-0001-6376-9077/work/82959084https://hdl.handle.net/2164/15313Funding and disclosure The authors declare the following financial and biomedical conflict of interests: Ruth A. Ross, Catharine A. Mielnik, Amy J. Ramsey, Iain R. Greig, Laurent A. Trembleau, Mostafa H. Abdelrahman are co-inventors on a patent application related to ABM300 and structural analogs. Kim S. Sugamori, David B. Finlay, Hayley H.A. Thorpe, Matthieu Schapira, Nirunthan Sivananthan, Chun Kit Li, Vincent M. Lam, Sean Harrington, W. McIntyre Burnham, Jibran Y. Khokhar, Ali Salahpour, Michelle Glass reported no biomedical financial interests or potential conflicts of interest. W. McIntyre Burnham received Δ9- (THC) as a gift from MedReleaf. The authors would like to gratefully acknowledge Wendy Horsfall for mouse colony maintenance. The work was funded by grants to RAR from CIHR (PPP-125784, PP2-139101), CIHR funding to AJR (MOP119298) and CIHR funding to AS (PJT-15619).1013357132934890engSDG 3 - Good Health and Well-beingcannabinoidAllosteric modulatorpsychosishyperdopaminergiapharmacologysensorimotor processingR MedicinePsychiatry and Mental healthPharmacologySupplementary DataRA novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent modelsJournal article10.1038/s41386-020-00876-5http://www.scopus.com/inward/record.url?scp=85092394943&partnerID=8YFLogxK462